Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

56.22 -2.28 (-3.90%)
Official Closing Price Updated: 7:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
66 67 Next >
Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme
It's still unclear whether CMS will include those drugs in its negotiation list. 
Via Investor's Business Daily
Got $5,000? These 2 High-Yielding Dividend Stocks Are Near Their 52-Week Lows
These are blue chip stocks you can hold in your portfolio for many years. 
Via The Motley Fool
Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments
From Bristol Myers Squibb
Via Business Wire
Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation
Via Benzinga
How Is The Market Feeling About Bristol-Myers Squibb?
Via Benzinga
Where Bristol-Myers Squibb Stands With Analysts
Via Benzinga
This Big Pharma Stock Is a Clear Buy
This drugmaker is one of the most well-known in the world. 
Via The Motley Fool
A Bearish Sign Appears On Bristol-Myers Squibb's Chart
Via Benzinga
Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023
From Bristol Myers Squibb
Via Business Wire
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023
Via Benzinga
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Receives European Commission Approval of Reblozyl® (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
From Bristol Myers Squibb
Via Business Wire
The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor
From Bristol Myers Squibb
Via Business Wire
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) ….
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Participate in Cowen’s 43rd Annual Health Care Conference
From Bristol Myers Squibb
Via Business Wire
7 Dividend Stocks to Buy During a Market Downturn
If you are still in search of total returns in this down market, then looking for dividend stocks to buy is a smart strategy for your portfolio. 
Via InvestorPlace
Bristol Myers Squibb to Present Data Supporting its Cardiovascular Portfolio at the American College of Cardiology Annual Scientific Session Together With World Congress of Cardiology
From Bristol Myers Squibb
Via Business Wire
Why Nektar Therapeutics Stock Is Plunging Today
Via Benzinga
Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:AZN),(NYSE:BMY),(NYSE:AMAM),(NYSE:GSK) EQNX::TICKER_END 
Via FinancialNewsMedia
This Recession-Proof Company Has a Best-in-Class Dividend
Pfizer's highly attractive valuation, rock-solid dividend program, and enormous yield put it at the top of its big pharma peer group. 
Via The Motley Fool
3 Dirt-Cheap Stocks to Buy Sooner Rather Than Later
These pharmaceutical stocks probably won't stay so attractively valued for too much longer. 
Via The Motley Fool
I ‘Tricked’ ChatGPT Into Picking Stocks to Buy. Here’s What It Said.
We asked ChatGPT to name various types of stocks to buy. Can the latest artificial intelligence craze get things right? 
Via InvestorPlace
Bristol Myers' Opdivo Shows Improved Clinical Benefits In Bladder Cancer At Three Years
Via Benzinga
Adjuvant Opdivo (nivolumab) Continues to Provide Significant, Durable Clinical Benefits for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma After Three Years in CheckMate -274 Trial
From Bristol Myers Squibb
Via Business Wire
A Patent Cliff Is Coming For Bristol — Can Billions In New Products Fill The Gap?
The company's biggest moneymakers are soon to lose patent protection. 
Via Investor's Business Daily
Basketball Legend Kareem Abdul-Jabbar Joins No Time to Wait Campaign to Raise Awareness of Atrial Fibrillation (AFib) and its Symptoms
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb-Exelixis Highlight Three-Year Follow Up Data From Opdivo+Cabometyx Combo Therapy In Kidney Cancer
Via Benzinga
Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers
Large cap biopharma stocks are off their highs despite reasonable valuations plus dividends. 
Via Talk Markets
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
From Bristol Myers Squibb and Exelixis, Inc.
Via Business Wire
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
66 67 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS